AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell

Go back to AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
AbbVie (NYSE: ABBV) Delayed: 284.80 -4.28 (1.48%)
Previous Close $289.08    52 Week High $68.12 
Open $287.63    52 Week Low $50.71 
Day High $289.00    P/E 61.78 
Day Low $282.15    EPS $4.61 
Volume 4,394,198       

(NASDAQ: GMAB) Delayed: 39.57 +0.50 (1.28%)
Previous Close $39.07    52 Week High $ 
Open $39.08    52 Week Low $ 
Day High $39.66    P/E N/A 
Day Low $39.05    EPS $ 
Volume 3,106,117